Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) yesterday and set a price target of $101.00. The company’s shares closed yesterday at ...

In trading on Tuesday, shares of Globus Medical Inc (Symbol: GMED) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $78.6301 per share. By comparison ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $100.00. The company’s shares closed yesterday at ...